Spectral Medical CMO Dr. John Kellum to Present at the 27th International AKI & CRRT Conference on March 7-10, 2022
04 März 2022 - 2:00PM
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:
EDT), a late stage theranostic company advancing
therapeutic options for sepsis and septic shock, as well as
commercializing a new proprietary platform targeting the renal
replacement therapy market through its wholly-owned subsidiary
Dialco Medical Inc. (Dialco), announces that the Company’s Chief
Medical Officer, Dr. John Kellum, has been selected to present at
the 27th International Conference on Advances in Critical Care
Nephrology (AKI and CRRT 2022), taking place on March 7-10, 2022 at
the Hilton San Diego Bayfront in San Diego, California.
-
On Monday, March 7, Dr. Kellum will participate in the plenary
session, in a talk entitled, “Sepsis Phenotypes and Risk of Acute
Kidney Injury (AKI),” where he will discuss the scientific
rationale for endotoxemia as a molecular phenotype of sepsis
causing AKI and other organ failures.
-
On Tuesday, March 8, Spectral is co-sponsoring a workshop on blood
purification “Differentiating Hemopurification Therapies –
Practical Applications of Pathogen & Endotoxin
Reduction,” where Dr. Kellum will present EUPHRATES to TIGRIS:
Targeting Endotoxemia in Septic shock.
-
On March 10 at 11:30 AM, Dr. Sobia Khan, site investigator for the
TIGRIS trial at Stony Brook University, will present an update on
the trial for the session, “Future Trends in CRRT and Critical Care
- Update from Ongoing and Late Breaking Trials.”
- The company will also have an
exhibition booth to promote the SAMI device at the conference,
where visitors will have the opportunity to meet with members of
the senior management team.
About International AKI & CRRT
Conference
The International Acute Kidney Injury (AKI)
& Continuous Renal Replacement Therapy (CRRT) Conference
provides a comprehensive review of advances in clinical care,
research and technology in critical care medicine with a focus on
the kidney and renal support techniques. Invited lectures,
workshops, dedicated sessions for nursing, poster sessions and
panel discussions are planned to continue the tradition of
multidisciplinary during the conference. This year’s program again
promises to provide the right environment to foster learning and
mutually beneficial interactions and collaborations. For more
information, please visit: https://crrtonline.com/.
About Spectral
Spectral is a Phase III company seeking U.S. FDA
approval for its unique product for the treatment of patients with
septic shock, Toraymyxin™ (“PMX”). PMX is a
therapeutic hemoperfusion device that removes endotoxin, which can
cause sepsis, from the bloodstream and is guided by the Company’s
Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic
for the risk of developing sepsis.
PMX has been approved for therapeutic use in
Japan and Europe, and has been used safely and effectively on more
than 300,000 patients to date. In March 2009, Spectral obtained the
exclusive development and commercial rights in the U.S. for PMX,
and in November 2010, signed an exclusive distribution agreement
for this product in Canada. Approximately 330,000 patients are
diagnosed with severe sepsis and septic shock in North America each
year.
Spectral, through its wholly owned subsidiary,
Dialco Medical Inc., is also commercializing a new set of
proprietary platforms addressing renal replacement therapy
(“RRT”) across the dialysis spectrum. SAMI is
targeting the acute RRT market, while DIMI is targeting the chronic
RRT market. Dialco is currently pursuing regulatory approval for
U.S. in-home use of DIMI, which is based on the same RRT platform
as SAMI, but will be intended for home hemodialysis use. DIMI
recently received its FDA 510k clearance for use in hospital and
clinical settings, and obtained its Health Canada license for use
within Canadian hospitals, clinics and in home.
Spectral is listed on the Toronto Stock Exchange
under the symbol EDT. For more information, please visit
www.spectraldx.com.
Forward-looking statement
Information in this news release that is not
current or historical factual information may constitute
forward-looking information within the meaning of securities laws.
Implicit in this information, particularly in respect of the future
outlook of Spectral and anticipated events or results, are
assumptions based on beliefs of Spectral's senior management as
well as information currently available to it. While these
assumptions were considered reasonable by Spectral at the time of
preparation, they may prove to be incorrect. Readers are cautioned
that actual results are subject to a number of risks and
uncertainties, including the availability of funds and resources to
pursue R&D projects, the successful and timely completion of
clinical studies, the ability of Spectral to take advantage of
business opportunities in the biomedical industry, the granting of
necessary approvals by regulatory authorities as well as general
economic, market and business conditions, and could differ
materially from what is currently expected.
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
Contact:
Mr. Chris Seto |
Mr. Ali Mahdavi |
David Waldman/Natalya Rudman |
CEO |
Capital Markets & Investor
Relations |
US Investor Relations |
Spectral Medical Inc. |
Spinnaker Capital Markets
Inc. |
Crescendo Communications,
LLC |
416-626-3233 ext. 2004 |
416-962-3300 |
212-671-1020 |
cseto@spectraldx.com |
am@spinnakercmi.com |
edt@crescendo-ir.com |
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Spectral Medical (TSX:EDT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024